Replies to post #28075 on DNAprint Genomics (DNAG)

[dr frudaky]

geob

The Dutchess deal does not seem to calculate well for the shareholders.

Assuming a 10 for 1 r/s, there will be 1.4 billion a/s for securing the 35 million from Dutchess over two years. The current pps is 0.01080. Since Dutchess will be buying at a 4% discount, they will only pay 0.01037 for each share. This will require 3.375+ billion shares to fulfill that deal at the current pps. Since the company will only have 1.4 billion a/s, where will the remaining 1.975+ billion shares come from? Even if Frudakis gets shareholder approval to print those additional 1.5 billion new a/s he was talking about some time ago, that still leaves a deficit of 475+ million shares. This is astonishing to say the least.

Of course, I have assumed the current pps will stay the same. More than likely it will drop to subpenny after the r/s, and particularly if Frudakis prints those additional 1.5 billion new shares. If that happens, you will have to significantly increase the number of shares required to fulfill that Dutchess deal. Mind boggling to say the least.

JMHO from the facts.

dr f

Are we expecting a huge miracle revenue deal for DNAP?

[Easyman51]

It seems a fair deal, Geo, if management provides the necessary means to "up" the value of the share price. I have been critical of their ability to do so these last couple of years. Confidence level has fallen to sub penny in Richards "hold 'em" possition w/ parcity of substantive PR's.

Most of my pessimism originated from the failed BioFrontera Deal which undercut those "secure pinnings" promised in the personalized medicine program promoted by Msrs. Gabriel. This seeming affiliation w/ PharmEco thru a subsidiary was viewed by investors a strong connection he brought to the Board. My subsequent view was equally influenced to the negative after it was revealed that although the pipeline products in their portfolio had viablility, the finacials were unsustainable. It would appear to me, even at this late date, that the money aspect would have been one of the first elements to consider in acquisitioning. It was during this time and for this purpose that I personally felt the LJG Commitment was made. As a shareholder, I feel duped in this regards and would hope that someone who attends the shareholder meeting addresses this aspect. Perhaps I my confused conclusions in this can be cleared up. I hope so, for if memory serves me, we had a substainable .05 pps level prior to this and it was the push for recognition w/ WSG, etc. that added to the upscale of debt ratio that is weighing DnaPrint down. From my limited viewpoint, we already had the necessary exposure in Forensics to bring in that present cash flow and Ancestery being promoted in their different areas could have been established w/out great expenditure. Like I have said, I am not a "bean counter" but our increased exposure hasn't done much for the bottom line.

Here it is at it's basic level for me. Whenever Dr. Frudakis speaks about technical advancements, I am opptomistically invigorated in my view of the potential value of my investment.
He is abreast in the R&D view, but I don't see where Richard has brought about the realization. Ok, I am impatient, but I can't see handing Richard a blank check based on his current history here.

Easy